Engineering Biomaterials to Direct Innate Immunity

31Citations
Citations of this article
54Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Small alterations during early stages of innate immune response can drive large changes in how adaptive immune cells develop and function during protective immunity or disease. Controlling these events creates exciting potential in the development of immune engineered vaccines and therapeutics. This progress report discusses recent biomaterial technologies exploiting innate immunity to dissect immune function and to design new vaccines and immunotherapies for infectious diseases, cancer, and autoimmunity. Across these examples, an important idea is the possibility to co-opt innate immune mechanisms to enhance immunity during infection and cancer. During inflammatory or autoimmune disease, some of these same innate immune mechanisms can be manipulated in different ways to control excess inflammation by promotion of immunological tolerance.

Cite

CITATION STYLE

APA

Oakes, R. S., Froimchuk, E., & Jewell, C. M. (2019, June 1). Engineering Biomaterials to Direct Innate Immunity. Advanced Therapeutics. Blackwell Publishing Ltd. https://doi.org/10.1002/adtp.201800157

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free